Lobbying Report: 340B Health (Q2 2026)
July 20, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This report identifies the specific federal bills and regulatory actions that 340B Health is actively lobbying on, which may influence future changes to drug pricing policies and hospital reporting requirements.
Potentially affected actors named in the source documents. Mention is not a position.
340B Health
The organization is the registrant and client, responsible for reporting its lobbying activities and expenditures.
Hospitals participating in the 340B program
These entities are represented by 340B Health and are subject to the legislative and regulatory changes monitored by the organization.
Last recorded activity July 20, 2026.
Next step not available in the current record.
Summary
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is 340B Health?
How much did 340B Health spend on lobbying this quarter?
What specific issues were they focused on?
Why It Matters
This report identifies the specific federal bills and regulatory actions that 340B Health is actively lobbying on, which may influence future changes to drug pricing policies and hospital reporting requirements.
News Coverage
Lobbying Activity
The Cleveland Clinic Foundation
on behalf of Cleveland Clinic Foundation
2026
“Quantum computing Immigration Issues National Institute of Health CHILDReN Act EARLY Minds Act Interoperability Issues Brain Health 340B Graduate Medical Education Workforce Issues Payer Accountability Organ Transplant Legislation Healthy Competition Act Price Transparency ”
340B Health
2026
“The SECURE 340B Act (H.R. 9599); The Tax-Exempt Hospital Transparency Act (H.R.9504); 340B PATIENTS Act (H.R. 4581/S.2372); Community Health Center Drug Pricing Protection Act (H.R. 7391); 2027 OPPS Proposed Rule; Information Collection Request Title: 340B Rebate Model Pilot Program Application, Implementation, and Evaluation, OMB Number 0906-NEW; Manufacturer Demand for Access to in-House Pharmacy Claims Data; Lilly 340B Drug Pricing Denial; HRSA Rebate Model Pilot pending regulation; Pending Senate "Gang of Six" draft 340B legislation; FY27 Appropriations legislation; Pending introduction of updated and expanded Community Health Center Drug Pricing Protection Act.”
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Rebate Model Pilot
The organization is heavily focused on the HRSA Rebate Model Pilot, indicating a significant shift in regulatory oversight for 340B drug pricing.
Connected Entities
Sources
disclosurespreview.house.gov
Analysis Score
0–100- Significance60How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools